Aimee Wilkin to Drug Resistance, Viral
This is a "connection" page, showing publications Aimee Wilkin has written about Drug Resistance, Viral.
Connection Strength
0.073
-
Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results. Antivir Ther. 2016; 21(1):55-64.
Score: 0.033
-
Townsend D, Troya J, Maida I, Pérez-Saleme L, Satta G, Wilkin A, Barreiro P, Pegram PS, Soriano V, Mura MS, Núñez M. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct; 8(5):314-7.
Score: 0.022
-
Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007 Dec; 23(12):1505-14.
Score: 0.019